InvestSMART

Noxopharm Limited (ASX:NOX)

ALERT: Price-sensitive ASX Announcement for NOX
Current share price for NOX : $0.091 0.027 (42.19%)+
Announcement
Release
20 May 2026 9:21AM
Price at Release
$0.064
Full Release
download
Summary
Noxopharm Limited announced that their Sofra™ technology platform will be featured at the Options for the Control of Influenza XIII Conference in Washington DC. The presentation by CSL will focus on how Noxopharm’s novel oligonucleotides can enhance the delivery of self-amplifying mRNA vaccines. This platform, developed from a breakthrough discovery in the immune system, comprises a novel class of drugs targeting inflammatory and autoimmune diseases, RNA therapeutics, and vaccines. The Sofra platform has potential applications in conditions such as rheumatoid arthritis, lupus, diabetes, and oncology, demonstrating significant versatility and industry interest.
Key Points
  • Noxopharm’s Sofra assets will be presented at a global conference.
  • The presentation will be by CSL at the Options for the Control of Influenza XIII Conference.
  • Focus on improving delivery of self-amplifying mRNA vaccines.
  • Sofra is a novel class of drugs targeting immune-related diseases.
  • Potential applications include rheumatoid arthritis, lupus, diabetes, and oncology.
  • Sofra’s versatility and immune system understanding are attracting industry attention.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.